At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials enrollment ending with over 10,000 participants, the company is waiting for approval.
There is no specific medicine for dengue yet. If ongoing Phase III trials yield positive results, an effective, affordable & specific antiviral would be available, 'ultimately saving more lives'.
Over four billion people are currently at risk from mosquito-borne infections, including dengue, Zika, and chikungunya. It's estimated to rise to five billion by 2050.
With govt's local clinical trials waiver for certain drugs and vaccines, Japanese firm Takeda may soon launch QDenga, which will be a boost for India’s fight against dengue.
Most number of cases in southern states, Maharashtra. Experts stress need for policy & community action, say global warming may have contributed to proliferation of source mosquitoes.
This preprint study is 1st to demonstrate anti-SARS-CoV-2 antibodies can cross-react with dengue virus serotype and enhance its infection through antibody-dependent enhancement.
Takeda's QDENGA, designed to protect against all 4 dengue virus serotypes, has been recommended by Strategic Advisory Group of Experts on Immunization for use in endemic countries.
Dengue fever, caused by the Aedes mosquito, has long been a concern in tropical and subtropical regions, including parts of Asia, Latin America, and the Caribbean.
Takeda has carried out phase 3 trials of the vaccine candidate and found it to be 80.2% effective in preventing symptomatic dengue cases after a year of vaccination.
The collusion between the new class of bureaucrats, politicians, businessmen and trade union bosses perpetuates itself partly because of the short-run benefits and partly because they see no way out of the system, wrote author MH Mody in 1980.
IAF is firming up plans to revamp airlift capabilities with medium transport aircraft that will be assembled in India & serve as its main workhorse. Embraer is leading contender as of now.
COMMENTS